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C ardio-oncology (the cardiovascular care of patients with cancer) has emerged as a new medical discipline, mostly because of targeted cancer therapies, which are effective in cancer treatment but which can cause cardiovascular complications. 1 Cardiovascular sequalae of these targeted therapies, which interfere with specific intracellular signaling pathways, may also provide insights into human cardiovascular biology. 2 As an example, cardiovascular complications that arise after treatment with vascular endothelial growth factor (VEGF) inhibitors have provided a growing appreciation of VEGF signaling in cardiovascular homeostasis and cardiovascular disease. 2 VEGFA, secreted by tumors, plays a critical role in angiogenesis through binding VEGF receptors and activating VEGF signaling pathway (VSP). 3 Targeting this pathway (via VEGF inhibitors, also known as VSP inhibitors) has become an important means to treat various cancer types, with 12 such therapies having been approved over the past decade. Most of these therapies are small molecular multitargeted tyrosine kinase inhibitors with sunitinib being the first drug approved. The tyrosine kinase inhibitors in this class can target multiple tyrosine kinase receptors although each is potent against the 3 VEGF receptors: VEGFR1, VEGFR2, and VEGFR3. 1 VSP inhibitors also cause many cardiovascular complications, including cardiomyopathy, vascular events, and hypertension. Of these, hypertension is the most common. 4 An absolute blood pressure increase is observed 1 week after initiating VSP inhibitors with both systolic and diastolic blood pressure affected. The frequency of hypertension has prompted algorithms by clinicians to recognize and treat the hypertension; however, an intriguing question has been the mechanisms of hypertension and the general relevance of VEGF signaling in vascular tone and vascular biology.
Current data suggest the involvement of several mechanisms for VEGF inhibitor-induced hypertension; much of this is based on plausible biology. 4, 5 VEGF induces the production of several vasodilators, including nitric oxide and prostacyclin, and decreases endothelin-1, a potent vasoconstrictor. Conversely, experimental evidence from both preclinical models and human data suggests that treatment with VSP inhibitors decreases nitric oxide bioavailability and increases endothelin-1. In addition, VEGF is expressed in endothelial cells and in the kidney: in both settings playing an important role in cellular proliferation and homeostasis. The data here are less convincing, but small studies suggest that VSP inhibitors can directly cause glomerular level injury, leading to renovascular hypertension. Still another possibility (with even less direct evidence) is that VSP inhibitors may promote anatomic (eg, capillary rarefaction) or functional changes in the microvasculature, in this way increasing total peripheral resistance and contributing to hypertension.
In this issue of Hypertension, Lankhorst et al 6 explore the possibility of another mechanism of VSP inhibitorinduced hypertension. To fully appreciate the author's elegant approach, some background is provided here. It has been known for some time that sodium plays an important pathophysiological role in the development of hypertension, with epidemiological studies showing that the increase in BP occurring with age is determined by salt intake. Until recently, it was assumed that the kidney is the key regulator of sodium and water. Specifically, in select individuals, salt-sensitive hypertension occurs because of an impaired renal capacity to excrete salt, leading to salt retention, blood volume expansion, and hypertension. More recently, it has become evident body sodium content is variable, does not always equilibrate with water, and is not exclusively controlled by the kidneys. Ground-breaking studies by Titze 7 have shown that large amounts of sodium are stored in the skin and skeletal muscle and contribute to hypertension.
These data suggest that the traditional model for electrolyte and water homeostasis, which considers the intravascular and interstitial space as 1 functional extracellular compartment, is an oversimplification. In addition, the interstitial space is a distinct compartment that relies on tissue-specific regulatory mechanisms for controlling its electrolyte content. Titze and colleagues have additionally shown that macrophages, by infiltrating the sites of sodium (and chloride) overload in the skin, sense the interstitial electrolyte composition and secrete a VEGF family member cytokine (VEGFC). 8, 9 VEGFC interaction with VEGF receptors (mostly likely VEGFR3) results
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in hyperplasia of lymph capillary vessels (Figure) . This process is compensatory; failure of this local extrarenal macrophage-dependent control mechanism to regulate interstitial electrolyte and water homeostasis results in arterial hypertension and disturbances in skin electrolyte composition. 8, 9 With this background in mind, Lankhorst et al 6 hypothesized that sunitinib, by virtue of inhibiting VEGF signaling, would impair this compensatory macrophage-dependent clearance of skin lymphangiogenesis after salt loading, further contributing to hypertension. The authors used a rat model of sunitinib-induced hypertension established previously in the laboratory. They first established that both high-salt diet and sunitinib significantly increased blood pressure with sunitinib further increasing blood pressure in high-salt-induced hypertension model. As expected, high-salt diet increased urinary sodium excretion and skin sodium content. Sunitinib did not affect urinary sodium excretion or plasma sodium concentration. A trend in further elevation of skin sodium was seen when sunitinib was added to high-salt diet; however, this did not reach statistical significance. As expected, salt loading in rats led to an increase in macrophage cell infiltration and lymphangiogenesis in the skin. However, sunitinib did not attenuate this effect.
This study has several limitations. First, sunitinib was given well after salt intake was started (2 weeks). Second, sunitinib was given for 8 days, a duration and dose which may not have been sufficient to reverse the macrophage-dependent lymphangiogenesis. Third, the authors' assessment of renal function is limited, given that glomerular filtration rate was not directly measured. In this regard, VEGF inhibition has been demonstrated previously to impair renal function. 10 Finally, the authors do little to assess the effects of combination of sunitinib and high-salt diet on other accepted mechanisms of sunitinib-associated hypertension, nicely demonstrated previously using their model.
Further studies will be needed to assess the role that macrophages play in skin electrolyte homeostasis in the setting of VEGF inhibitors. Newer and more potent VEGF inhibitors are being tested (and approved) for cancer treatment, with these therapies (perhaps in part because of more potent inhibition of VEGF signaling) leading to hypertension in a larger percentage of patients. A phase I/II trial with the new tyrosine kinase inhibitor lucitanib, for example, leads to hypertension in 91% of patients with an additional 57% having proteinuria. 11 One powerful approach to cardio-oncology research is the ability to do clinical studies with the patient's baseline (before getting the cancer treatment) serving as a control. In this regard, it is possible to test the hypothesis that tissue sodium content contributes to hypertension in humans. For example, recently, it has become possible to measure the concentration of Na + in the tissue of humans via a noninvasive technique using 23 Na-magnetic resonance imaging. 12 These studies have already been used to demonstrate an increased local sodium storage in humans who have hyperaldosteronism, hypernatremia, and hypertension. 13 A similar approach may be tested in patients being treated with VEGF inhibitors in practice to further not only the mechanism of hypertension in the cardiooncology population but also establish the role of VEGF in extrarenal regulation of electrolytes in humans.
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Figure.
A schematic model for tissue sodium (Na + ) contributing to hypertension. High salt leads to accumulation of interstitial sodium in the skin. This is sensed by macrophages, which increase release of vascular endothelial growth factor C (VEGFC). This results in lymphangiogenesis and leads to moderation of blood pressure. Inhibition of this process may be one mechanism by which sunitinib treatment results in elevated blood pressure.
